Nrx pharmaceuticals (nasdaq: nrxp) to present keynote address on ketamine efficacy and risks at upcoming sachs neuroscience innovation forum in san francisco

The benefits of ketamine are clear, but so are the risks ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patients nrx to file a new drug application for ketamine to treat suicidal depression in 2024 in us and eu radnor, pa. , jan. 2, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", (nrx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled "ketamine for suicidal depression: the benefits are clear, but so are the risks," at the upcoming sachs neuroscience innovation forum in san francisco, ca on january 7, 2024.
NRXP Ratings Summary
NRXP Quant Ranking